Literature DB >> 7834685

[Etiologic study on the relationship between HBV, HCV and HCC].

B Ye1, J Shen, Y Xu.   

Abstract

A total of 110 HCC patients were sampled randomly in 20 townships of Qidong county (a higher incidence area of HCC in China) from Mar. to Sept. 1989. Each patient was paired with two healthy persons as control. The results showed that the prevalences of HBV and HCV in 110 patients were 85.45% and 17.27% respectively, and were significantly higher that in control (50.45% and 4.09%). Using Conditional Logistic Regression Model. we found that the main risk factors of HCC in Qidong were HBsAg and Pre-S2 for HBV and anti-HCV for HCV. The OR value were 10.22, 2.96 and 2.63, respectively. Drinking tea was the only protective factor (OR = 0.36). Among 110 HCC patients. 13.64% were positive for both HBV and HCV. The OR value was the highest (6.48). 88.18% patients were either HBV or HCV positive. The OR values were similar (3.90 and 3.89). It suggests that the most important risk factor of HCC in Qidong was HBV infection because it had a higher prevalence among the population while the HCV infection having an equal OR value was also a risk factor.

Entities:  

Mesh:

Year:  1994        PMID: 7834685

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  3 in total

1.  Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection.

Authors:  Zhihua Liu; Jinlin Hou
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

2.  Low prevalence of hepatitis C infection in hepatocellular carcinoma (HCC) cases and population controls in Guangxi, a hyperendemic region for HCC in the People's Republic of China.

Authors:  J M Yuan; S Govindarajan; B E Henderson; M C Yu
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

3.  A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China.

Authors:  J Shi; L Zhu; S Liu; W-F Xie
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.